These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 37296912)
1. Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? Nevola R; Delle Femine A; Rosato V; Kondili LA; Alfano M; Mastrocinque D; Imbriani S; Perillo P; Beccia D; Villani A; Ruocco R; Criscuolo L; La Montagna M; Russo A; Marrone A; Sasso FC; Marfella R; Rinaldi L; Esposito N; Barberis G; Claar E Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296912 [TBL] [Abstract][Full Text] [Related]
3. Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time? Boilève J; Guimas V; David A; Bailly C; Touchefeu Y Curr Oncol; 2024 May; 31(6):3199-3211. PubMed ID: 38920726 [TBL] [Abstract][Full Text] [Related]
4. Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma. Wang C; Wei F; Sun X; Qiu W; Yu Y; Sun D; Zhi Y; Li J; Fan Z; Lv G; Wang G Front Oncol; 2024; 14():1429919. PubMed ID: 38993637 [TBL] [Abstract][Full Text] [Related]
5. Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art. Laschtowitz A; Roderburg C; Tacke F; Mohr R J Hepatocell Carcinoma; 2023; 10():181-191. PubMed ID: 36789252 [TBL] [Abstract][Full Text] [Related]
6. Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review. Chamseddine S; LaPelusa M; Kaseb AO Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444618 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Su YY; Li CC; Lin YJ; Hsu C Semin Liver Dis; 2021 Aug; 41(3):263-276. PubMed ID: 34130338 [TBL] [Abstract][Full Text] [Related]
8. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Llovet JM; Pinyol R; Yarchoan M; Singal AG; Marron TU; Schwartz M; Pikarsky E; Kudo M; Finn RS Nat Rev Clin Oncol; 2024 Apr; 21(4):294-311. PubMed ID: 38424197 [TBL] [Abstract][Full Text] [Related]
9. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma. Zhang B; Yue J; Shi X; Cui K; Li L; Zhang C; Sun P; Zhong J; Li Z; Zhao L BMJ Open; 2022 Sep; 12(9):e060955. PubMed ID: 36115673 [TBL] [Abstract][Full Text] [Related]
10. Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. da Fonseca LG; Araujo RLC World J Gastroenterol; 2022 Jul; 28(28):3573-3585. PubMed ID: 36161045 [TBL] [Abstract][Full Text] [Related]
11. Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better? Dikilitas M J Gastrointest Cancer; 2020 Dec; 51(4):1193-1196. PubMed ID: 32869146 [TBL] [Abstract][Full Text] [Related]
12. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Zhang W; Zhang B; Chen XP Front Med; 2021 Apr; 15(2):155-169. PubMed ID: 33754281 [TBL] [Abstract][Full Text] [Related]
14. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Lau WY; Lai EC; Lau SH Hepatobiliary Pancreat Dis Int; 2009 Apr; 8(2):124-33. PubMed ID: 19357024 [TBL] [Abstract][Full Text] [Related]
15. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Schipilliti FM; Garajová I; Rovesti G; Balsano R; Piacentini F; Dominici M; Gelsomino F Pharmaceuticals (Basel); 2021 Jan; 14(1):. PubMed ID: 33429973 [TBL] [Abstract][Full Text] [Related]
16. Overview of resistance to systemic therapy in patients with breast cancer. Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229 [TBL] [Abstract][Full Text] [Related]
17. Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review. Wang H; Qian YW; Dong H; Cong WM Hepatobiliary Surg Nutr; 2024 Jun; 13(3):472-493. PubMed ID: 38911201 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions. Li L; Li ZZ; Pan LX; Su JY; Huang S; Ma L; Zhong JH J Clin Transl Hepatol; 2024 May; 12(5):525-533. PubMed ID: 38779519 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Samuel M; Chow PK; Chan Shih-Yen E; Machin D; Soo KC Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD001199. PubMed ID: 19160192 [TBL] [Abstract][Full Text] [Related]
20. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]